Abstracts tagged "SLE"

Abstract Number: 2895 • 2018 ACR/ARHP Annual Meeting
Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial
Sara K. Tedeschi¹, Cynthia Aranow², Diane L. Kamen³, Meryl S. LeBoff⁴, Betty Diamond² and Karen Costenbader⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Bone health in SLE is adversely affected by vitamin D deficiency, inflammatory cytokines including interferon (IFN)-α, and glucocorticoid use. We tested the hypothesis that…
Abstract Number: 93 • 2018 ACR/ARHP Annual Meeting
Biomarkers Associating Endothelial Function in Systemic Lupus Erythematous
Wan-Fang Lee¹, Chao-Yi Wu², Huang-Yu Yang³ and Jing-Long Huang^2,4, ¹Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ²Division of Allergy, Asthma and Rheumatology. Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ³Department of Nephrology,, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ⁴Medicine, Chang-Gung University, Taoyuan city, Taiwan
Background/Purpose: The endothelium is a key element in the regulation of vascular homeostasis and its alteration is a precursor of vascular disease. Considering SLE is…
Abstract Number: 749 • 2018 ACR/ARHP Annual Meeting
Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Joan T. Merrill¹ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁴Nephrology Division, UT Southwestern Medical Center, Dallas, TX, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus Nephritis (LN) usually presents within 5 years of SLE diagnosis, however the minority of patients with late-occurring nephritis are poorly characterized. Factors associated…
Abstract Number: 1095 • 2018 ACR/ARHP Annual Meeting
IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus
Wietske Lambers¹, Geert Lanting¹, Wayel H. Abdulahad², Hendrika Bootsma², Johanna Westra² and Karina de Leeuw³, ¹Rheumatology/Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Incomplete systemic lupus erythematosus (iSLE) includes patients with typical features of SLE, who do not meet classification criteria. Still, up to 50% will develop…
Abstract Number: 2019 • 2018 ACR/ARHP Annual Meeting
Investigating Urine S100A4 and Podocyte Proteins As Biomarkers of Lupus Nephritis Activity
Jessica Turnier¹, Jianghong Deng², Pinar Ozge Avar Aydin³, David Witte⁴, Prasad Devarajan⁵, Matthew Fenchel⁶, Michael Bennett⁷ and Hermine I. Brunner⁸, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Beijing Children’s Hospital and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁶Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: We lack accurate clinical tools to identify the degree of active renal inflammation in childhood-onset SLE (cSLE). In this study, we investigated urine S100A4…
Abstract Number: 2184 • 2018 ACR/ARHP Annual Meeting
An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Ann E. Clarke¹, Tom Goss², Andrew Piscitello³, Tarun Chandra³, Tyler O'Malley⁴, Thierry Dervieux⁴ and Tami Powell⁵, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Health Economics Outcomes Research, Boston Healthcare, Boston, MA, ³EmpiriQA LLC, Long Grove, IL, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Corporate Payer Strategy & Reimbursement, Exagen Diagnostics, Inc., vista, CA
Background/Purpose: Diagnosis (dx) of systemic lupus erythematosus (SLE) is made via a combination of clinical and laboratory examinations; the sensitivity and specificity (S&S) of standard…
Abstract Number: 2971 • 2018 ACR/ARHP Annual Meeting
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes
Joanna Tieu^1,2, Seerapani Gopaluni^3,4, Rona Smith¹ and David Jayne¹, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Cambridge, Cambridge, United Kingdom, ⁴Vasculitis and Lupus, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background/Purpose: Despite a low incidence of hypogammaglobulinemia (HG) in clinical trials using rituximab (RTX), HG occurs in follow-up of patients with autoimmune disease. Immunoglobulin replacement…
Abstract Number: 97 • 2018 ACR/ARHP Annual Meeting
Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Ayako Makiyama², Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake², ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Type I interferon(IFN) appears to contribute to the development of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes has been reported…
Abstract Number: 753 • 2018 ACR/ARHP Annual Meeting
Young SLE Patients Have Higher Coronary Artery Calcium Scores Compared with Population Controls
Yevgeniya Gartshteyn¹, Genna Braverman², Sharan Mahtani³, Kayla Neville⁴, George Danias⁴, Laura Geraldino-Pardilla⁵, Sabahat Bokhari⁶ and Anca Askanase⁷, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Internal Medicine, Columbia University Medical Center, New York, NY, ³College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom, ⁴Rheumatology, Columbia University Medical Center, New York, NY, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁶Cardiology, Columbia University, NY, NY, ⁷Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of death in systemic lupus erythematosus (SLE). The coronary artery calcium (CAC) score is a surrogate for…
Abstract Number: 1098 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Timothy B. Niewold¹, Alexander Meves², Julia S. Lehman³, Karin Popovic-Silwerfeldt⁴, Cristine Charlesworth⁵, Marie Wahren-Herlenius⁶, Elisabet Svenungsson⁷ and Vilija Oke⁸, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Cancer Cenetr, Dermatology, Mayo Clinic, Rochester, MN, ³Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁴Department of Clinical Sciences, Dermatology Clinic, Danderyds Hospital,, Stockholm, Sweden, ⁵Mayo Clinic, Rochester, MN, ⁶Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases. The histopathological pattern of skin involvement can be similar, i.e. interface dermatitis, but the…
Abstract Number: 2089 • 2018 ACR/ARHP Annual Meeting
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Anselm Mak¹, Bhushan Dharmadhikari², Lik Wei Wong², Saji Kumar Sreedharan² and Herbert Schwarz², ¹Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Costimulatory molecules which mediate cross-talks between leukocytes, have been identified to play a pathogenetic pivotal role in systemic lupus erythematosus (SLE). Abrogation of the…
Abstract Number: 2356 • 2018 ACR/ARHP Annual Meeting
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Cristina Arriens¹, Fredonna Carthen², D'Angelo Grant², Paul Kamp¹, Stan Kamp¹, Katherine Thanou¹, Teresa Aberle¹, Eliza Chakravarty¹, Judith A. James³, Joan T. Merrill¹ and Motolani E. Ogunsanya⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, OKLAHOMA CITY, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials. This may lead to false, underpowered conclusions in race-based sub-group…
Abstract Number: 102 • 2018 ACR/ARHP Annual Meeting
Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms
Julian F. Oviedo¹, Elena N. Cravens¹ and Vaishali R. Moulton^2,3, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Medicine/Rheumatology, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic debilitating autoimmune disease that primarily afflicts women in the childbearing years. Female hormones especially estrogen are implicated…
Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
Meera Tarazi¹, Carolyn Kushner², Rebecca Gaffney² and Victoria P. Werth³, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Dermatology, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…
Abstract Number: 1099 • 2018 ACR/ARHP Annual Meeting
Ongoing DNA Damage, Chromatin Deregulation and Defective DNA Damage Response in Systemic Autoimmune Rheumatic Diseases
Maria Pappa¹, Nikolaos I. Vlachogiannis¹, Alexandra Argyriou¹, Vassilis L. Souliotis² and Petros Sfikakis³, ¹National Kapodistrian University of Athens Medical School, Athens, Greece, First Department of Propaedeutic and Internal Medicine & Rheumatology Unit, National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ²National Hellenic Research Foundation, Athens, Greece, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Recent data highlight that patients with Systemic Lupus Erythematosus (SLE) have defects in two main DNA repair pathways, namely nucleotide excision repair (NER) and…

« Previous Page
1
…
8
9
10
11
12
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].